Low rates of HPV vaccination and cervical cancer screening: Challenges and opportunities in the context of the COVID-19 pandemic.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35461955.
- Also identified by DOI 10.1016/j.ypmed.2022.107070 and PMC identifier 9022394.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This invited commentary discusses the article by Richards et al. describing differences in rates of on-time HPV vaccination and cervical cancer screening in 2018 among enrollees in different insurance plans. The commentary focuses on the larger problem of low vaccination HPV rates and decreasing cervical cancer screening rates seen across all sectors. We outline challenges posed by the COVID-19 pandemic on HPV vaccination and cervical cancer screening, and discuss opportunities to improve cervical cancer prevention.
Medical subject headings
- COVID-19
- Papillomavirus Infections
- Papillomavirus Vaccines
- Uterine Cervical Neoplasms